|Bid||0.00 x 1200|
|Ask||0.00 x 800|
|Day's Range||87.61 - 92.71|
|52 Week Range||64.72 - 126.98|
|Beta (3Y Monthly)||2.16|
|PE Ratio (TTM)||875.69|
|Earnings Date||Feb 5, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||105.31|
SAN DIEGO, Jan. 16, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) today announced that a new analysis of INGREZZA® (valbenazine) capsules, published in the Journal of Affective Disorders1, demonstrated sustained improvement in tardive dyskinesia (TD) symptoms in patients with primary mood disorders. In the post-hoc analysis, INGREZZA significantly reduced involuntary movements associated with TD in patients with a primary mood disorder, such as bipolar and major depressive disorder, and was generally well tolerated with no clinically meaningful changes to psychiatric stability. INGREZZA is the first U.S. Food and Drug Administration (FDA) approved treatment for adults with TD, a movement disorder that is characterized by uncontrollable, abnormal and repetitive movements of the face, torso and/or other body parts.
Biotechnology companies have been hit so hard, Big Pharma is now picking them off one by one in takeovers. This makes biotech companies look very attractive. In the weakness, for example, Celgene (CELG) hit its lowest price-to-earnings ratio in history, or around six.
SAN DIEGO, Jan. 15, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) announced today that it will report fourth quarter and year-end 2018 financial results after the Nasdaq market closes on Tuesday, Feb. 5, 2019. Neurocrine will then host a conference call and webcast to discuss its financial results and provide a Company update that day at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time). Participants can access the live conference call by dialing 877-876-9174 (US) or 785-424-1669 (International) using the conference ID: NBIX.
NEW YORK, NY / ACCESSWIRE / January 14, 2019 / U.S. equities posted strong weekly gains, however, stock closed lower for the day on Friday on concerns over an ongoing U.S. government shutdown and worries ...
The Nasdaq Biotechnology Index, a bellwether of investor sentiment, has seen a 13 percent jump in 2019 after Bristol-Myers Squibb Co. kicked off the year with a record takeout of Celgene Corp. The nine-day winning streak is the longest in five years and the best start to a year since the index was created in 1993. The broader S&P 500 is up 3.6 percent year to date, while the S&P 500 Health Care Index is up just 1.6 percent. “It really is amazing how investor sentiment can turn on a dime and how it takes one piece of big news to do that,” Brad Loncar, chief executive of Loncar Investments, said in an interview at the conference in San Francisco.
Kevin Gorman has been the CEO of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) since 2008. First, this article will compare CEO compensation with compensation at similar sized companies. Next, we'll consider growth Read More...
Biotech stocks are already making some big waves this year. That's because M&A activity is already surging. Drawn by some big-time values, some of the world's biggest pharmaceutical firms have gone shopping for beaten-down biotech bargains. Already, we've seen Bristol-Meyers (NYSE:BMY) score Celgene (NASDAQ:CELG) for a cool $74 billion in a game-changing acquisition. More recently, Eli Lilly (NYSE:LLY) announced that it was pushing harder into cancer treatments with an $8 billion offer for Loxo Oncology (NASDAQ:LOXO). The question on everyone's minds is "who is next?" InvestorPlace - Stock Market News, Stock Advice & Trading Tips With plenty of biotech stocks still trading for peanuts and coffers overflowing at the major pharma's, more M&A activity is guaranteed. And while betting on a buyout may be a fool's errand, there are plenty of biotech stocks out there are on my best stocks to invest in list anyway. A buyout would be icing on the cake. * Morgan Stanley: 7 Risky Stocks to Sell Now But which ones have the potential to snagged up because they are so good? Here are five biotech stocks that could be buy-out candidates. Source: Shutterstock ### Seattle Genetics (SGEN) With oncology and cancer on the minds of many of the biggest names pharma, biotech stock Seattle Genetics (NASDAQ:SGEN) could once again be in play. SGEN has one drug available for patients -- Adcetris -- which is used to treat Stage III/IV classical Hodgkin lymphoma. Sales of Adcetris continue to grow rapidly. In the last reported quarter, revenues for the drug jumped by over 60% year-over-year. Even better is that number of indications, combinations and other uses for Adcetris have grown like weeds. SGEN continue to rack up more approvals and "breakthrough" designations for the drug. All of this has only made the medicine more lucrative for the biotech stock. As if that wasn't enough for big pharma to be salivating at the firm, Seattle Genetics has been able to pivot its technology towards other forms of cancer. The firm has numerous drugs targeting urothelial, cervical, breast and multiple myeloma cancer varieties. Here again, SGEN has been quite successful in moving its drugs through the FDA's hoops. Given growing sales of Adcetris and its heavy-duty cancer-focused pipeline, any biopharma looking to make a splash in oncology would seriously be considering SGEN stock. With a market cap of just over $11 billion, Seattle Genetics could one of the next biotech stocks to be bought out. Source: Shutterstock ### Agios Pharmaceuticals (AGIO) Keeping with the cancer buy-out theme, Agios Pharmaceuticals (NASDAQ:AGIO) makes an intriguing biotech buyout candidate. AGIO has two cancer therapies on the market. Its latest, Tibsovo, has been approved for those acute myeloid leukemia patients with an IDH1 mutation. The other -- Idhifa -- is for acute myeloid leukemia patients who also test positive for an IDH2 mutation. The firm basically has a one-two punch for this specific variety of leukemia. And while the drugs are new, prescriptions are growing, with Tibsovo seeing a 100% quarter-over-quarter increase in its short life span. That makes it a buyout candidate alone. Tibsovo is wholly owned by Agios. However, the real kicker is that Idhifa came via a partnership with Celgene. Celgene -- soon to be Bristol Meyers -- must continue to pay royalties on sales from the drug via a tiered structure that gets into the mid-teens. Given its buyout of CELG, BMY may just want to control the whole pie, and with AGIO's market cap sitting at just over $3 billion, it's an easy pill to swallow. And with the two medicines, BMY would be getting a healthy pipeline of additional cancer therapies as well as some rare disease work for a song. * 10 Stocks You Can Set and Forget (Even In This Market) Given that, there's a good chance that AGIO gets the nod. No wonder why shares have jumped higher since both CELG's and LOXO's buyout bids. Source: Shutterstock ### Jazz Pharmaceuticals (JAZZ) It's very rare to find biotech stocks trading for bargain-basement valuations. But that's just what is happening at Jazz Pharmaceuticals (NASDAQ:JAZZ). Today, you can snag JAZZ stock for forward P/E of under 10. JAZZ has five drugs on the market, with narcolepsy drug Xyrem being a blockbuster. Sales of Xyrem continue to grow and are expected to surpass $1.4 billion this year. At the same time, its portfolio of hematology/oncology drugs are proven to be winners as well and are helping JAZZ realize a double-digit EPS growth rate. Acute myeloid leukemia treatment Vyxeos, which only launched last year, is set to pull in roughly $100 million in sales for the full year 2018 and more than $200 million this year. Adding to this is JAZZ's pending March approval for its new drug covering excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea. Another late-stage candidate for cataplexy in narcolepsy should hit regulatory approval at the end of the year. With a rich drug portfolio and pipeline, JAZZ is a rarity among biotech stocks. It's profitable -- so much so that the firm has authorized a $400 million buyback program. That's after it already repurchased over $600 million in shares. Analysts estimate that a dividend could even be coming next. Featuring a market cap of less than $8 billion, JAZZ would be an easy and profitable tuck-in for almost any big pharma stock. Source: Shutterstock ### Neurocrine Biosciences (NBIX) A rare miss for Neurocrine Biosciences (NASDAQ:NBIX) sent shares crashing this year and left the firm with a $7.5 billion market cap. But NBIX's pain could end up being AbbVie's (NASDAQ:ABBV) gain. Over the summer, NBIX and ABBV received an FDA approval for their drug Orilissa, which is used in the treatment of pain associated with endometriosis. The drug is currently wrapping up trials for the treatment of uterine fibroids. Analysts think the drug has blockbuster potential with annual sales of around $1 billion. On its own, NBIX has a blockbuster in Ingrezza. The drug is used to treat tardive dyskinesia -- which is marked by jerky movements of the face and body out of a patient's control. The problem is tardive dyskinesia is a side effect of many depression, schizophrenia and other mental health drugs. This is a huge market, and Ingrezza sales are taking off. Management at Neurocrine estimates that they'll be able to pull in over $400 million in Ingrezza sales in 2018. And NBIX has a full pipeline of other drugs in various stages of trials. With a buyout, ABBV gets full access to Orilissa without royalty and milestone fees for future indications. Secondly, Ingrezza is quickly becoming a major money marker for NBIX. That would fill a nice hole in AbbVie's revenue stream and would help pay for the deal over the long haul. * The 7 Best Stocks in the Entrepreneur Index All in all, given its low market cap, hefty cash balance and marketed drugs, AbbVie may end up swallowing NBIX whole. Source: Shutterstock ### BioMarin Pharmaceutical (BMRN) When politicians and pundits often talk about the high price of drugs and mention therapies costing more than $400,000 per year, odds are, they are talking about rare and orphan diseases. For biotech stocks, targeting these diseases -- which sometimes can affect very small population sizes -- it can mean plenty of long-term revenues down the road. Given the research required to crack these afflictions, the high drug prices are more than justified. BioMarin (NASDAQ:BMRN) is one biotech stock that has made rare diseases its specialty. The firm has seven drugs on the market targeting illnesses such as phenylketonuria and Batten disease. Rare disease medications come with longer exclusivity rights and by focusing here, BMRN basically ensures patient protection versus generic competition. At the same time, these drugs pull in some big-time revenues. For example, this year, BioMarin expects to make more than $1.5 billion in sales with its top five drugs. Meanwhile, the biotech stocks pipeline is rich as well with drugs for hemophilia and sanfilippo in late-stage trials. Because of its focus, profitability and rich rare disease pipeline, BioMarin has long been considered a buy candidate. With big pharma finally starting to spend some dough, that takeover may finally happen. At the time of writing, Aaron Levitt had a long position in CELG and JAZZ ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Stocks You Can Set and Forget (Even In This Market) * 10 Virtual Assistants for the Future of Smart Homes * 7 5G Stocks to Buy as the Race for Spectrum Tightens Compare Brokers The post 5 Biotech Stocks That Could Face M&A Next! appeared first on InvestorPlace.
# Neurocrine Biosciences Inc ### NASDAQ/NGS:NBIX View full report here! ## Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low ## Bearish sentiment Short interest | Positive Short interest is low for NBIX with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ## Money flow ETF/Index ownership | Positive ETF activity is positive. Over the last month, growth of ETFs holding NBIX is favorable, with net inflows of $9.07 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to firstname.lastname@example.org. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Why Neurocrine Biosciences Stock Rose 9.6% Yesterday ## Stock performance On January 7, Neurocrine Biosciences (NBIX) stock rose ~9.57% to reach $81.86 from its prior close of $74.71 on January 4. Also, on January 4, the company’s stock price grew ~7.79% to reach $74.71 from its prior-day close of $69.31 on January 3. The stock’s closing price on January 7 was a ~26% increase from its 52-week low of $64.72 on December 12, 2018. The company hit its 52-week high of $126.98 on September 13, 2018. ## Reason for the stock price rise On January 6, Neurocrine Biosciences (NBIX) presented its preliminary results for the fourth quarter and full-year 2018. Neurocrine Biosciences expects that its fourth-quarter 2018 net sales will be around $130.0 million compared to $64.5 million in the fourth quarter of 2017, representing 102% YoY growth. The company anticipates its net sales for full-year 2018 to be around $409.0 million compared to $116.6 million in fiscal 2017. Neurocrine Biosciences also provided program milestones for 2019. The company anticipates submitting a new drug application to the FDA for approval of Opicapone for the treatment of Parkinson’s disease in the second quarter of 2019. Neurocrine Biosciences expects data from the phase 2a trial of NBI-74788 for the treatment of adults with congenital adrenal hyperplasia (or CAH). The company also expects to initiate a phase 2a trial of NBI-74788 on pediatric patients with CAH. Neurocrine Biosciences anticipates initiating the pivotal trial of NBI-74788 for adults with CAH during the second half of 2019. The company will discuss the pivotal trial in the second quarter of 2019 with the FDA. ## Analysts’ recommendations Of 16 analysts tracking Neurocrine Biosciences in January 2019, six of them recommended a “strong buy,” while nine analysts recommended a “buy” rating. One analyst recommended a “hold” for the company in January 2019. On January 7, Neurocrine Biosciences had a consensus 12-month target price of $108.75, which represents a ~32.85% return on investment over the next 12 months.
Neurocrine (NBIX) issues preliminary sales outlook for Ingrezza with respect to the fourth quarter of 2018 as well as the full year. The company also lends an update on its pipeline.
Neurocrine Biosciences (NASDAQ:NBIX) has been around since 1992 and went public in 2003, though it still isn't exactly on the tip of investors' tongues. But that's already starting to change. In the past year, the stock was up more than 50% at one point, but then got hit with the market woes as well as the fact that one of its drugs in the pipeline for Tourette's syndrome didn't get the results it had hoped to achieve. As with most biotech and pharma firms, a setback on a drug can set back the stock as well. And while NBIX has a market cap of more than $6 billion and has development agreements with major pharma companies, it's going to get hit harder than bigger stocks simply because it has fewer drugs in the pipeline than other companies. The setback on one drug could make it harder to keep its burn rate -- the amount of money the company is spending on developing and testing its drugs -- manageable. InvestorPlace - Stock Market News, Stock Advice & Trading Tips This news and the secular downturn has certainly laid NBIX stock low -- it's off 33% in the past three months and 9% for the past year. At this point, it's a C-rated stock in my Portfolio Grader … but it's one worth watching. ### Why You Should Watch NBIX Stock When a stock hits a C rating, it could be because it's falling apart and trying to stay competitive and relevant. Or, it could be it's been oversold in a tough market and has what it takes to make it back, but it may take a while. For NBIX, the latter is closer to the truth. * 10 Top Stock Picks From the Street's Best Analysts Its TS study was bad news for its current drug Ingrezza, but Ingrezza is already doing better than expected in its current category. And the fact that Neurocrine simply pulled the drug from further TS studies shows that it's not too proud to move that money along to other projects that have more promise. Plus, its pipeline has other promising drugs in it and interested partners. The company's focus on neurology and endocrinology drugs makes it attractive because it's a niche that few are in. And its success in these sectors also makes it an attractive partner. Most of its drugs on the market have competitors, NBIX generally has competitive advantages, either in pricing or in dosing. And being able to get these drugs to market with a strong partner like AbbVie (NYSE:ABBV) -- partners on Orilissa, a drug for uterine fibroids -- means that it can leave the heavy lifting on the marketing side to a powerful, experienced partner. When you have big partners, it means you can negotiate better deals with pharmacy benefit management companies and you all get to access their field reps so you get your drug into the hands of more doctors. But this market is still jumpy, so stock news is also dictated by market and sector news at this point. This is a long-term pick because it has drugs ready to roll out for the next couple of years and collectively they could spell big opportunities. There's also the possibility that a big pharma may want to snap up NBIX stock to add to its portfolio. It's worth keeping an eye on. Louis Navellier is a renowned growth investor. He is the editor of four investing newsletters: Growth Investor, Breakthrough Stocks, Accelerated Profits and Platinum Growth. His most popular service, Growth Investor, has a track record of beating the market 3:1 over the last 14 years. He uses a combination of quantitative and fundamental analysis to identify market-beating stocks. Mr. Navellier has made his proven formula accessible to investors via his free, online stock rating tool, PortfolioGrader.com. Louis Navellier may hold some of the aforementioned securities in one or more of his newsletters. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Downtrodden Stocks to Fish From the Bottom * 8 Cheap Value Stocks That Just Got More Enticing * 5 Apple Suppliers Hurt by the Guidance Cut Compare Brokers The post Neurocrine Biosciences Is a Pharma Stock to Watch appeared first on InvestorPlace.
NEW YORK, NY / ACCESSWIRE / January 7, 2019 / U.S. markets surged on Friday as employment data came in well above expectations. The Bureau of Labor Statistics reported 312,000 jobs were added in December, ...
SAN DIEGO, Jan. 6, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) today provided an update on its business performance, including preliminary net product sales results for 2018, and key clinical development programs for 2019. Kevin Gorman, Chief Executive Officer of Neurocrine, will discuss these updates as part of a webcast presentation at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, Jan. 7 at 2:30 p.m. PT (5:30 p.m. ET).
San Diego-based Neurocrine Biosciences (NBIX) is a biotechnology firm specializing in the development of treatments for neurological and endocrine diseases and disorders. Warning! GuruFocus has detected 2 Warning Signs with NBIX. Although the stock has had a rough few months, losing around 45% from its 2018 highs, Neurocrine's strong pipeline could bring the company back in the long term.
SAN DIEGO, Jan. 2, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) will present at the 37th Annual J.P. Morgan Healthcare Conference at 2:30 p.m. PT (5:30 p.m. ET) on Monday, Jan. 7, 2019, in San Francisco. Kevin Gorman, Chief Executive Officer, will present at the conference. Neurocrine Biosciences, a San Diego based biopharmaceutical company, is focused on developing treatments for neurological and endocrine related disorders.
Investors need to pay close attention to Neurocrine Biosciences (NBIX) stock based on the movements in the options market lately.
NEW YORK, NY / ACCESSWIRE / December 13, 2018 / Shares of both Neurocrine Biosciences and Synergy Pharmaceuticals were in the red on Wednesday after announcing discouraging developments. Synergy is selling its business assets while Neurocrine Biosciences failed to meet a primary goal in a mid-stage trial. Neurocrine Biosciences, Inc. shares were down almost 14% on about 13 million shares traded yesterday.
Today, Neurocrine Biosciences (NBIX) is trading at $67.91, a ~20.83% fall from its closing price of $85.76 on December 11. Neurocrine stock has hit its 52-week low of $64.72. Neurocrine stock was trading at $103.0 at the close of market on November 12, and it reached $85.69 on December 11, representing a ~17% fall in the month.
Neurocrine Biosciences Inc. said Wednesday a midstage trial of a treatment for Tourette syndrome in children and adolescents failed to meet its primary goal. The Phase IIb study found valbenazine did not meet the primary endpoint of reducing tic severity in young people with moderate to severe versions of the disease. "We are very disappointed with the topline data from the T-Force GOLD study given that children and adolescents with Tourette syndrome need better treatment options," Chief Executive Kevin Gorman said in a statement. "This study was well-conducted with a placebo response as expected, but the treatment effect of valbenazine was lower than we had anticipated." The company will further review the data to decide on its next steps, he said. Tourette syndrome is a neurological disorder marked by motor and vocal tics, including grimacing, head jerks and extremity movements. The average age for onset is six years and symptoms can reach peak severity around age 10. Neurocrine Biosciences shares were halted premarket for the news, but have gained about 11% in 2018, while the S&P 500 has fallen 1.4%.
SAN DIEGO, Dec. 12, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) today announced topline data from the Phase IIb T-Force GOLD study demonstrating that valbenazine did not meet the primary endpoint as assessed by the Yale Global Tic Severity Scale (YGTSS) in children and adolescents with moderate to severe Tourette syndrome. "We are very disappointed with the topline data from the T-Force GOLD study given that children and adolescents with Tourette syndrome need better treatment options. This study was well-conducted with a placebo response as expected, but the treatment effect of valbenazine was lower than we had anticipated," said Kevin Gorman, Ph.D., Chief Executive Officer at Neurocrine Biosciences.
During the first half of the fourth quarter the Russell 2000 ETF (IWM) lagged the larger S&P 500 ETF (SPY) by about 4 percentage points as investors worried over the possible ramifications of rising interest rates. The hedge funds and institutional investors we track typically invest more in smaller-cap stocks than an average investor (i.e. […]